Institution
Health Sciences Authority
Government•Singapore, Singapore•
About: Health Sciences Authority is a government organization based out in Singapore, Singapore. It is known for research contribution in the topics: Population & Mass spectrometry. The organization has 435 authors who have published 369 publications receiving 7712 citations. The organization is also known as: Penguasa Sains Kesihatan.
Topics: Population, Mass spectrometry, Certified reference materials, Isotope dilution, High-performance liquid chromatography
Papers published on a yearly basis
Papers
More filters
••
Emory University1, University of Verona2, National Institutes of Health3, King's College London4, Queen Mary University of London5, University of Modena and Reggio Emilia6, Leiden University7, Center for Cell and Gene Therapy8, Tulane University9, University of Wisconsin-Madison10, Health Sciences Authority11, St George's Hospital12, Karolinska Institutet13, University Hospital of Basel14, University of Texas MD Anderson Cancer Center15, Agency for Science, Technology and Research16, University of Pittsburgh17, Scripps Research Institute18, French Institute of Health and Medical Research19, Soochow University (Suzhou)20, Chinese Academy of Sciences21, University Health Network22, University of Vermont23
TL;DR: The International Society for Cellular Therapy (ISCT) addressed the issue at an international workshop in May 2015 as part of the 21st ISCT annual meeting in Las Vegas as mentioned in this paper.
364 citations
••
TL;DR: Postmortem lung sections from 8 patients who died from SARS during the spring 2003 Singapore outbreak studied, finding the predominant pattern of lung injury in all 8 cases was diffuse alveolar damage, and the histology varied according to the duration of illness.
358 citations
••
Johns Hopkins University School of Medicine1, Utrecht University2, University of Turin3, Agency for Science, Technology and Research4, University of Modena and Reggio Emilia5, Paracelsus Private Medical University of Salzburg6, La Trobe University7, Health Sciences Authority8, St. George's University9, Boston Children's Hospital10, University of Pittsburgh11, Kyoto University12, National University of Singapore13, University of Vermont14, Southern Medical University15, University of Duisburg-Essen16
TL;DR: MSC-sEVs should be defined by quantifiable metrics to identify the cellular origin of the sEVs in a preparation, presence of lipid-membrane vesicles, and the degree of physical and biochemical integrity of the vesicle.
Abstract: Small extracellular vesicles (sEVs) from mesenchymal stromal/stem cells (MSCs) are transiting rapidly towards clinical applications. However, discrepancies and controversies about the biology, functions, and potency of MSC-sEVs have arisen due to several factors: the diversity of MSCs and their preparation; various methods of sEV production and separation; a lack of standardized quality assurance assays; and limited reproducibility of in vitro and in vivo functional assays. To address these issues, members of four societies (SOCRATES, ISEV, ISCT and ISBT) propose specific harmonization criteria for MSC-sEVs to facilitate data sharing and comparison, which should help to advance the field towards clinical applications. Specifically, MSC-sEVs should be defined by quantifiable metrics to identify the cellular origin of the sEVs in a preparation, presence of lipid-membrane vesicles, and the degree of physical and biochemical integrity of the vesicles. For practical purposes, new MSC-sEV preparations might also be measured against a well-characterized MSC-sEV biological reference. The ultimate goal of developing these metrics is to map aspects of MSC-sEV biology and therapeutic potency onto quantifiable features of each preparation.
342 citations
••
TL;DR: The clinical use of miRNA signatures as a noninvasive diagnostic strategy is promising, but should be further validated for different subtypes of breast cancers.
Abstract: Purpose: There is a quest for novel noninvasive diagnostic markers for the detection of breast cancer. The goal of this study is to identify circulating microRNA (miRNA) signatures using a cohort of Asian Chinese patients with breast cancer, and to compare miRNA profiles between tumor and serum samples. Experimental Design: miRNA from paired breast cancer tumors, normal tissue, and serum samples derived from 32 patients were comprehensively profiled using microarrays or locked nucleic acid real-time PCR panels. Serum samples from healthy individuals ( n = 22) were also used as normal controls. Significant serum miRNAs, identified by logistic regression, were validated in an independent set of serum samples from patients ( n = 132) and healthy controls ( n = 101). Results: The 20 most significant miRNAs differentially expressed in breast cancer tumors included miRNA (miR)-21, miR-10b, and miR-145, previously shown to be dysregulated in breast cancer. Only 7 miRNAs were overexpressed in both tumors and serum, suggesting that miRNAs may be released into the serum selectively. Interestingly, 16 of the 20 most significant miRNAs differentially expressed in serum samples were novel. MiR-1, miR-92a, miR-133a, and miR-133b were identified as the most important diagnostic markers, and were successfully validated; receiver operating characteristic curves derived from combinations of these miRNAs exhibited areas under the curves of 0.90 to 0.91. Conclusion: The clinical use of miRNA signatures as a noninvasive diagnostic strategy is promising, but should be further validated for different subtypes of breast cancers. Clin Cancer Res; 19(16); 4477–87. ©2013 AACR .
253 citations
••
European Medicines Agency1, Massachusetts Institute of Technology2, Agence française de sécurité sanitaire des produits de santé3, Harvard University4, Novartis5, Commonwealth Fund6, National Institute for Health and Care Excellence7, AstraZeneca8, Bristol-Myers Squibb9, Health Sciences Authority10, Health Canada11, Food and Drug Administration12, Johnson & Johnson13, Canadian Agency for Drugs and Technologies in Health14, Aetna15, Pfizer16, Friends of Cancer Research17, Ohio Northern University18
TL;DR: This article summarizes recent adaptive licensing proposals; discusses how proposals might be translated into practice, with illustrations in different therapeutic areas; and identifies unresolved issues to inform decisions on the design and implementation of AL.
Abstract: Traditional drug licensing approaches are based on binary decisions. At the moment of licensing, an experimental therapy is presumptively transformed into a fully vetted, safe, efficacious therapy. By contrast, adaptive licensing (AL) approaches are based on stepwise learning under conditions of acknowledged uncertainty, with iterative phases of data gathering and regulatory evaluation. This approach allows approval to align more closely with patient needs for timely access to new technologies and for data to inform medical decisions. The concept of AL embraces a range of perspectives. Some see AL as an evolutionary step, extending elements that are now in place. Others envision a transformative framework that may require legislative action before implementation. This article summarizes recent AL proposals; discusses how proposals might be translated into practice, with illustrations in different therapeutic areas; and identifies unresolved issues to inform decisions on the design and implementation of AL.
252 citations
Authors
Showing all 436 results
Name | H-index | Papers | Citations |
---|---|---|---|
Choon Nam Ong | 86 | 444 | 25157 |
Kang Sim | 49 | 260 | 15441 |
Hark Hoe Tan | 48 | 542 | 10229 |
Shu-Chuen Li | 38 | 181 | 5465 |
Peng Zou | 36 | 128 | 6463 |
Cynthia Sung | 33 | 71 | 3503 |
Jeanette W. P. Teo | 29 | 116 | 2255 |
Eng Shi Ong | 29 | 52 | 2835 |
Mickey Koh | 27 | 100 | 2696 |
Min-Yong Low | 18 | 32 | 935 |
Heng Joo Ng | 17 | 90 | 1161 |
Ponnudurai Kuperan | 15 | 25 | 1216 |
Kellathur N. Srinivasan | 14 | 20 | 1043 |
Xiaowei Ge | 13 | 23 | 501 |
Gilbert Lau | 12 | 29 | 435 |